Divalproex Sodium ER Tablets USP, 250 mg and 500 mg, is the generic equivalent of Depakote® ExtendedRelease (ER) Tablets, 250 mg and 500 mg, of AbbVie Inc., indicated for:
• Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features
• Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures
• Prophylaxis of migraine headaches
Divalproex Sodium Extended-Release (ER) Tablets USP (RLD: Depakote® ER) had annual sales of approximately USD 130 million in the U.S. (IQVIA MAT July 2020).
Attention Investors
1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
2. Update your mobile number & email Id with your Stock Broker/Depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
3. Pay 20% upfront margin of the transaction value to trade in cash market segment.
4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 & 20200731-7 dated July 31, 2020 and NSE/INSP/45534 & 20200831-45 dated August 31, 2020 and other guidelines issued from time to time in this regard.
5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.